Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 104 participants.

Also called NCT03081598

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
Liminal BioSciences Ltd. (from the registry)
Registry
  • NCT NCT03081598
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03081598. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-29 (actual); primary completion 2018-09-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
PBI-4050
Intervention (Other)
Placebo
Lead sponsor
Liminal BioSciences Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03081598
Content hash
cf38827ec1269181e9a20bc26e6cb16f148f5675cb29f252f5ac3a6f2f9c4bde